Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial

BACKGROUND: There is currently a lack of effective treatments for non-small cell lung cancer (NSCLC) patients harboring HER2 mutations. We examined the efficacy and safety of, and potential resistance mechanism to, pyrotinib, a pan-HER inhibitor, in advanced NSCLC carrying HER2 mutations. METHODS: I...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Zhengbo, Li, Yuping, Chen, Shiqing, Ying, Shenpeng, Xu, Shuguang, Huang, Jianjin, Wu, Dan, Lv, Dongqing, Bei, Ting, Liu, Shuxun, Huang, Xiaoping, Xie, Congying, Wu, Xiaoyu, Fu, Jianfei, Hua, Feng, Wang, Wenxian, Xu, Chunwei, Gao, Chan, Cai, Shangli, Lu, Shun, Zhang, Yiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8805254/
https://www.ncbi.nlm.nih.gov/pubmed/35101045
http://dx.doi.org/10.1186/s12916-022-02245-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8805254/
https://www.ncbi.nlm.nih.gov/pubmed/35101045
http://dx.doi.org/10.1186/s12916-022-02245-z

Ejemplares similares